Clinical Trials
24 trialsNCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03907488 2026-05-04
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04099251 2026-04-09
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03143153 2026-02-17
CheckMate 648
Bristol-Myers Squibb
Phase 3 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT02743494 2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT02632409 2025-10-16
CheckMate 274
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04025879 2025-10-16
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04810078 2025-10-09
CheckMate-67T
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT02388906 2025-04-24
CheckMate 238
Bristol-Myers Squibb
Phase 3 Completed
NCT01928394 2024-12-27
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT02569242 2022-07-06
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 3 Completed